Inogen, Inc. (INGN) stock analysis

Healthcare · Medical Devices

From the 10-K filed 2026-02-27

Business type: Asset play

How it makes money

It generates revenue by selling and renting oxygen concentrators to patients and providers, with profit driven by reimbursement policies from government health programs.

It derives income from the sale and rental of its portable oxygen concentrators and respiratory products. Revenue recognition is heavily influenced by the ability of patients or providers to secure reimbursement for these medical devices.

Because the business depends on third-party payers like Medicare and Medicaid, its financial results are tied to the evolving rates and coverage methodologies determined by these government bodies.

What protects it: the moat

It relies on intellectual property protections for its proprietary concentrator technology, though management acknowledges that intense industry competition persists.

It attempts to build a competitive moat through patent filings for its proprietary Inogen One and Inogen Rove oxygen concentrator systems. These patents are intended to block competitors from replicating its mobility-focused respiratory technology.

However, management concedes that the respiratory market remains highly competitive, and the effectiveness of these protections is subject to legal challenge or circumvention by industry rivals.

What growth costs

It must continuously invest in research and development and the acquisition of new respiratory technologies to maintain its competitive standing.

To keep its product pipeline relevant, it directs capital toward the development of new respiratory devices and the enhancement of existing concentrators.

Additionally, it pursues inorganic growth through strategic acquisitions, such as the purchase of Physio-Assist, and formal collaborations to expand its product portfolio into new markets.

What could damage it

Future reductions in Medicare and Medicaid reimbursement rates could permanently impair its earnings by destroying the economic viability of its rental business model.

Because a significant portion of its revenue is dependent on complex reimbursement processes, a systemic downward shift in government payment rates directly threatens its ability to collect sufficient funds to cover the costs of its rental equipment and operations.

About Inogen, Inc.

Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It provides Inogen One and Inogen Rove, an ambulatory solution for long-term oxygen therapy; Rove 4, a portable oxygen concentrator; Rove 6 concentrator; Inogen Voxi 5, a stationary oxygen concentrator; Aurora for continuous positive airway pressure; CPAP masks; Simeox for airway clearance treatment; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Beverly, Massachusetts.

Other companies in Medical Devices